Agenus (NASDAQ:AGEN) Issues Quarterly Earnings Results

Agenus (NASDAQ:AGEN) announced its quarterly earnings data on Monday. The biotechnology company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of ($1.27) by $1.83, Zacks reports. The firm had revenue of $34.20 million during the quarter, compared to analyst estimates of $28.10 million.

Agenus Stock Performance

Shares of NASDAQ AGEN opened at $3.29 on Tuesday. The stock has a market cap of $111.89 million, a price-to-earnings ratio of -1.54 and a beta of 1.57. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $7.34. The firm’s 50-day simple moving average is $3.26 and its 200 day simple moving average is $3.77.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Agenus in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $14.50.

Institutional Trading of Agenus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EP Wealth Advisors LLC bought a new position in shares of Agenus in the fourth quarter valued at approximately $31,000. Quadrature Capital Ltd bought a new stake in Agenus during the fourth quarter worth $54,000. Squarepoint Ops LLC purchased a new stake in Agenus in the 3rd quarter valued at $54,000. Jump Financial LLC purchased a new stake in Agenus in the 2nd quarter valued at $55,000. Finally, Acadian Asset Management LLC bought a new position in Agenus during the 1st quarter valued at $58,000. 61.46% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.